Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Celgene will make an undisclosed payment and take a stake in Sutro Biopharma as part of a collaboration to develop antibody-drug conjugates and bispecific antibodies against two undisclosed disease targets. Sutro, which says it could collect up to $500 million if the programs reach the market, will also manufacture a Celgene antibody. In a separate deal, Shire will work with Arrowhead Research to develop peptide-drug conjugates. In addition to research funding, Arrowhead could earn up to $33 million for each drug candidate developed.
This article has been sent to the following recipient: